Please amend page 65, line 1 as follows:

~~Claims~~ **What is claimed is:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) An imaging agent which comprises a metalloproteinase inhibitor of Formula (I) labelled with an imaging moiety, wherein the imaging moiety can be detected following administration of said labelled matrix metalloproteinase inhibitor to the mammalian body *in vivo*:



(I)

where:

Y^1 is H or $-(CH_2)_w-(C{=}O)-Z$; where w is an integer of value 1 to 6; and

Z is OH, C_{1-6} alkoxy, C_{4-10} aryloxy or NR^1R^2 wherein R^1 and R^2 are each independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} fluoroalkyl or C_{4-10} aryl.

X^1 and X^2 together with the carbon atom to which they are attached, form a C_{3-10} saturated ring which may be alicyclic or bicyclic, and may optionally incorporate 1 or 2 heteroatoms chosen from O, N and S;

X^3 is H, C_{1-3} alkyl or C_{1-3} fluoroalkyl;

Y^2 is a group of formula $-[A^1]_p[O]_qA^2$ where p and q are 0 or 1, and A^1 is C_{1-10} alkylene, C_{3-8} cycloalkylene, C_{1-10} perfluoroalkylene, C_{6-10} arylene or C_{2-10}

heteroarylene, and A^2 is H, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{1-10} perfluoroalkyl, C_{6-10} aryl or C_{2-10} heteroaryl, with the proviso that when p=0, q is also 0 and A^2 is not H.

2. (Original) The imaging agent of Claim 1, where Y^1 is $-(CH_2)_w-(C=O)-Z$ and w is 1, 2 or 3.

3. (Currently Amended) The imaging agent of ~~Claims 1 or 2~~ Claim 1, where X^3 is H, CH_3 or CH_2F.

4. (Currently Amended) The imaging agent of ~~claims 1 to 3, wherein~~ Claim 1 where Y^2 is $-C_6H_4-O-A^2$, and A^2 is C_{6-10} aryl.

5. (Currently Amended)The imaging agent of ~~Claims 1 to 4~~ Claim 1, where the imaging moiety is chosen from:
   (i) a radioactive metal ion;
   (ii) a paramagnetic metal ion;
   (iii) a gamma-emitting radioactive halogen;
   (iv) a positron-emitting radioactive non-metal;
   (v) a hyperpolarised NMR-active nucleus;
   (vi) a reporter suitable for *in vivo* optical imaging;
   (vii) a ß-emitter suitable for intravascular detection.

6. (Currently Amended) The imaging agent of ~~Claims 1 to 5~~ Claim 1, where the imaging agent is of Formula II:



(II)

where:

{inhibitor} is the metalloproteinase inhibitor of Formula (I);

$-(A)_n-$ is a linker group wherein each A is independently $-CR_2-$, $-CR=CR-$, $-C\equiv C-$, $-CR_2CO_2-$, $-CO_2CR_2-$, $-NRCO-$, $-CONR-$, $-NR(C=O)NR-$, $-NR(C=S)NR-$, $-SO_2NR-$, $-NRSO_2-$, $-CR_2OCR_2-$, $-CR_2SCR_2-$, $-CR_2NRCR_2-$, a C_{4-8} cycloheteroalkylene group, a C_{4-8} cycloalkylene group, a C_{5-12} arylene group, or a C_{3-12} heteroarylene group, an amino acid, a sugar or a monodisperse polyethyleneglycol (PEG) building block;

R is independently chosen from H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxyalkyl or C_{1-4} hydroxyalkyl;
n is an integer of value 0 to 10; and
and X^a is H, OH, Hal, NH_2, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxyalkyl, C_{1-4} hydroxyalkyl or X^a is the imaging moiety.

7. (Original) The imaging agent of Claim 6, where the imaging moiety is attached at the Y^1 or Y^2 positions of the metalloproteinase inhibitor.

8. (Currently Amended) The imaging agent of ~~Claims 1 to 7~~ Claim 1, where the matrix metalloproteinase inhibitor is conjugated to a ligand, and said ligand forms a metal complex with the radioactive metal ion or paramagnetic metal ion.

9. (Original) The imaging agent of Claim 8, where the ligand is a chelating agent.

10. (Currently Amended) The imaging agent of ~~Claims 8 or 9~~ Claim 8, where the radioactive metal ion is a gamma emitter or a positron emitter.

11. (Original) The imaging agent of Claim 10, where the radioactive metal ion is ^{99m}Tc, ^{111}In, ^{64}Cu, ^{67}Cu, ^{67}Ga or ^{68}Ga.

12. (Original) The imaging agent of Claim 10, where the gamma-emitting radioactive halogen imaging moiety is ^{123}I.

13. (Original) The imaging agent of Claim 10, where the positron-emitting radioactive non-metal is chosen from ^{18}F, ^{11}C or ^{13}N.

14. (Currently Amended) The imaging agent of ~~Claims 1 to 13~~ Claim 1, where the matrix metalloproteinase inhibitor is of Formula IV:



(IV)

where: Y^2, w and Z are as defined in Claim 1;

X^3 is H, CH_3 or CH_2F;

X^4 is $-(CH_2)_m-$ where m is 1, 2 or 3, $-CH_2OCH_2-$ or X^5 where X^5 is



where t is 2 or 3.

15. (Original) The imaging agent of Claim 14, where Z is NR^1R^2.

16. (Currently Amended) The imaging agent of ~~Claims 14 or 15~~, Claim 1 where the matrix metalloproteinase inhibitor is of Formula V:



(V)

where:

X^6 is Hal, R^1 or OR^1, where R^1 is C_{1-3} alkyl or C_{1-3} fluoroalkyl.

17. (Original) The imaging agent of Claim 16, where Z is NR^1R^2, X^6 is F; and X^4 is –$(CH_2)_2$-,

-CH_2OCH_2- or X^5 with t equal to 2.

18. (Currently Amended) A pharmaceutical composition which comprises the imaging agent of ~~claims 1 to 17~~ Claim 1 together with a biocompatible carrier, in a form suitable for mammalian administration.

19. (Currently Amended) A radiopharmaceutical composition which comprises the imaging agent of ~~claims 1 to 17 wherein~~ Claim 1 where the imaging moiety is radioactive, together with a biocompatible carrier, in a form suitable for mammalian administration.

20. (Original) The radiopharmaceutical composition of claim 19, where the imaging moiety comprises a radioactive metal ion.

21. (Original) The radiopharmaceutical composition of claim 19, where the imaging moiety comprises a positron-emitting radioactive non-metal or a gamma-emitting radioactive halogen.

22. (Original) A conjugate of a matrix metalloproteinase inhibitor of Formula (I) as defined in Claim 1 with a ligand, wherein said ligand is capable of forming a metal complex with a radioactive or paramagnetic metal ion.

23. (Original) The conjugate of Claim 20, of Formula IIb:



(IIb)

where {inhibitor}, A, n and X^a are as defined in Claim 6.

24. (Currently Amended) The conjugate of ~~Claims 22 or 23~~,Claim 22 wherein the matrix metalloproteinase inhibitor is of Formulae IV ~~or V of Claims 14 to 17~~



(IV)

---

where: Y^2, w and Z are as defined in Claim 1;

X^3 is H, CH_3 or CH_2F;

X^4 is $-(CH_2)_m-$ where m is 1, 2 or 3, $-CH_2OCH_2-$ or X^5 where X^5 is



where t is 2 or 3 or wherein the matrix metalloproteinase inhibitor is of Formulae V



(V)

where:

X^6 is Hal, R^1 or OR^1, where R^1 is C_{1-3} alkyl or C_{1-3} fluoroalkyl.

25. (Currently Amended) The conjugate of ~~Claims 22 to 24~~, Claim 22 wherein the ligand is a chelating agent.

26. (Original) The conjugate of Claim 25, wherein the chelating agent has a diaminedioxime, N_2S_2, or N_3S donor set.

27. (Currently Amended) A kit for the preparation of the radiopharmaceutical composition of Claim 20. ~~which comprises the conjugate of Claims 22 to 26~~.

28. (Original) The kit of Claim 30, where the radioactive metal ion is ^{99m}Tc, and the kit further comprises a biocompatible reductant.

29. (Currently Amended) A kit for the preparation of the radiopharmaceutical composition of Claim 21, which comprises a precursor, said precursor being a non-radioactive derivative of the matrix metalloproteinase inhibitor of ~~claims 1 to 17~~, wherein said non-radioactive derivative is capable of reaction with a source of the positron-emitting radioactive non-metal or gamma-emitting radioactive halogen to give the desired radiopharmaceutical.

30. (Original) The kit of claim 29 where the precursor is in sterile, apyrogenic form.

31. (Currently Amended) The kit of ~~Claims 29 or 30~~ Claim 29, where the source of the positron-emitting radioactive non-metal or gamma-emitting radioactive halogen is chosen from:

    (i) halide ion or F^+ or I^+; or

    (ii) an alkylating agent chosen from an alkyl or fluoroalkyl halide, tosylate, triflate or mesylate.

32. (Currently Amended) The kit of ~~Claims 29 to 31~~, Claim 29 where the non-radioactive derivative is chosen from:

    (i) an organometallic derivative such as a trialkylstannane or a trialkylsilane;

    (ii) a derivative containing an alkyl halide, alkyl tosylate or alkyl mesylate for nucleophilic substitution;

    (iii) a derivative containing an aromatic ring activated towards nucleophilic or electrophilic substitution;

    (iv) a derivative containing a functional group which undergoes facile alkylation;

    (v) a derivative which alkylates thiol-containing compounds to give a thioether-containing product.

33. (Currently Amended) The kit of ~~claims 29 to 32~~ Claim 29, where the precursor is bound to a solid phase.

34. (Currently Amended) ~~Use~~ The imaging agent of Claim 1, ~~Claims 1 to 17~~ wherein the imaging agent is used for ~~the~~ diagnostic imaging of atherosclerosis.

35. (Currently Amended) ~~Use of the~~ The imaging agent of ~~Claims 1 to 17~~ Claim 1, wherein the imaging agent is used for ~~the~~ diagnostic imaging of unstable plaques.

36. (Currently Amended) ~~Use of the imaging agent of Claims 1 to 17~~ The imaging agent according to Claim 1, wherein the imaging is for the intravascular detection of atherosclerosis.